QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Arpino, P. A Articles by Hallisey, R. K Search for Related Content PubMed PubMed Citation Articles by Arpino, P. A Articles by Hallisey, R. K

CARDIOLOGY

Effect of Renal Function on the Pharmacodynamics of Argatroban

Senior Attending Pharmacist, Department of Pharmacy, Massachusetts General Hospital, Boston, MA

Robert K Hallisey, MS BSPharm

Drug Therapy Coordinator, Department of Pharmacy, Massachusetts General Hospital

Reprints: Paul A Arpino PharmD, Department of Pharmacy, Massachusetts General Hospital, 55 Fruit St., Boston, MA 02114-2696, FAX 617/726-9232, parpino{at}partners.org

BACKGROUND: Argatroban is a direct thrombin inhibitor used to treat heparin-induced thrombocytopenia (HIT). Argatroban is primarily cleared by hepatic mechanisms, with only small amounts of unchanged drug cleared by the kidneys.

OBJECTIVE: To assess the effects of renal function on argatroban dose and activated partial thromboplastin time (aPTT).

METHODS: Patients treated with argatroban were identified and prospectively screened. Patients with liver dysfunction were excluded from the analysis. Charts and laboratory data were reviewed daily until a therapeutic aPTT was reached or argatroban was discontinued. Data points collected included age, weight, gender, admitting diagnosis, past medical history, indication for anticoagulation, indication for argatroban, initial dose, goal aPTT, titration instructions, liver function tests, serum creatinine (S_cr), blood urea nitrogen, and estimated creatinine clearance (Cl_cr).

RESULTS: A total of 66 patients were evaluated and 44 met criteria for inclusion. Baseline S_cr was elevated at 1.5 mg/dL (0.9, 2.3; median 25th, 75th percentile), with an estimated Cl_cr 40 mL/min/1.73 m² (26, 74). The median dose of argatroban to reach the predefined therapeutic range was 1 µg/kg/min (0.68, 2), with a corresponding aPTT of 60 seconds (54, 66). After univariate analysis, Cl_cr significantly predicted the therapeutic dose (coefficient b ± SE 0.019 ± 0.004; r² 0.35; p < 0.001). Covariates that predicted dose were the presence of HIT (coefficient b ± SE –0.61 ± 0.3; p = 0.045), history of myocardial infarction (coefficient b ± SE –0.74 ± 0.3; p = 0.02), and an indication for anticoagulation of deep-vein thrombosis/pulmonary embolism (coefficient b ± SE 0.69 ± 0.3; p = 0.03).

CONCLUSIONS: Estimated Cl_cr significantly predicted the dose of argatroban needed to reach a therapeutic aPTT.

Key Words: argatroban, heparin-induced thrombocytopenia, renal insufficiency

Published Online, October 29, 2003. www.theannals.com, DOI 10.1345/aph.1D163

This article has been cited by other articles:

				S. Shaikh and E. M. Van Cott The Effect of Argatroban on Activated Protein C Resistance Am J Clin Pathol, June 1, 2009; 131(6): 828 - 833. [Abstract] [Full Text] [PDF]

				S. P Keegan, E. M Gallagher, N. E Ernst, E. J Young, and E. W Mueller Effects of Critical Illness and Organ Failure on Therapeutic Argatroban Dosage Requirements in Patients with Suspected or Confirmed Heparin-Induced Thrombocytopenia Ann. Pharmacother., January 1, 2009; 43(1): 19 - 27. [Abstract] [Full Text] [PDF]

				S. M. Begelman, S. B. Baghdasarian, I. M. Singh, M. A. Militello, M. J. Hursting, and J. R. Bartholomew Argatroban Anticoagulation in Intensive Care Patients: Effects of Heart Failure and Multiple Organ System Failure J Intensive Care Med, September 1, 2008; 23(5): 313 - 320. [Abstract] [PDF]

				T. E. Warkentin, A. Greinacher, A. Koster, and A. M. Lincoff Treatment and Prevention of Heparin-Induced Thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 340S - 380S. [Abstract] [Full Text] [PDF]

				W. D Hoffman, Y. Czyz, D. A McCollum, and M. J Hursting Reduced Argatroban Doses After Coronary Artery Bypass Graft Surgery Ann. Pharmacother., March 1, 2008; 42(3): 309 - 316. [Abstract] [Full Text] [PDF]

				M. Beiderlinden, T. A Treschan, K. Gorlinger, and J. Peters Argatroban Anticoagulation in Critically Ill Patients Ann. Pharmacother., May 1, 2007; 41(5): 749 - 754. [Abstract] [Full Text] [PDF]

				D. W Kubiak, P. M Szumita, and J. R Fanikos Extensive Prolongation of aPTT with Argatroban in an Elderly Patient with Improving Renal Function, Normal Hepatic Enzymes, and Metastatic Lung Cancer Ann. Pharmacother., June 1, 2005; 39(6): 1119 - 1123. [Abstract] [Full Text] [PDF]

				M. A. Smythe, W. E. Dager, and N. M. Patel Managing Complications of Anticoagulant Therapy Journal of Pharmacy Practice, October 1, 2004; 17(5): 327 - 346. [Abstract] [PDF]